Henry Schein, Inc. (NASDAQ:HSIC) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have received an average rating of “Hold” from the fourteen brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $76.6923.

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. raised their price target on shares of Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Barclays assumed coverage on Henry Schein in a report on Monday, December 8th. They issued an “overweight” rating and a $86.00 price objective for the company. Barrington Research set a $79.00 target price on Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, November 5th. Mizuho set a $81.00 price target on Henry Schein and gave the stock a “neutral” rating in a research note on Tuesday. Finally, Evercore ISI raised their price target on Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th.

Henry Schein Stock Performance

HSIC stock opened at $77.73 on Wednesday. Henry Schein has a 1 year low of $60.56 and a 1 year high of $82.49. The stock has a market capitalization of $9.15 billion, a price-to-earnings ratio of 24.60, a PEG ratio of 2.38 and a beta of 0.88. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.79 and a current ratio of 1.40. The stock’s fifty day moving average is $75.51 and its two-hundred day moving average is $70.56.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.27 by $0.11. The business had revenue of $3.34 billion during the quarter, compared to analyst estimates of $3.28 billion. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. On average, research analysts predict that Henry Schein will post 4.74 EPS for the current year.

Institutional Trading of Henry Schein

A number of hedge funds and other institutional investors have recently made changes to their positions in HSIC. CYBER HORNET ETFs LLC bought a new position in shares of Henry Schein in the second quarter valued at approximately $25,000. MUFG Securities EMEA plc acquired a new stake in Henry Schein in the second quarter worth approximately $27,000. ANTIPODES PARTNERS Ltd bought a new position in Henry Schein during the 2nd quarter valued at $43,000. Steph & Co. acquired a new position in shares of Henry Schein during the 2nd quarter valued at $44,000. Finally, CX Institutional raised its stake in shares of Henry Schein by 107.3% in the 2nd quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after buying an additional 337 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.